Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions

References

• Ackerman, S. J., & Hilsenroth, M. J. (2001). A review of therapist characteristics and techniques negatively impacting the therapeutic alliance. Psychotherapy: Theory/research/practice/training, 38(2), 171–185.
   Web of Science ®Google Scholar
• Addy, P. H. (2012). Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology, 220(1), 195–204.
   PubMed Web of Science ®Google Scholar
• Aghajanian, G. K., & Marek, G. J. (1999). Serotonin and hallucinogens. Neuropsychopharmacology, 21(2), 16S–23S.
   PubMed Web of Science ®Google Scholar
• Alnaes, R. (1964). Therapeutic application of the change in consciousness produced by psycholytica (LSD, Psilocybin, etc.). Acta Psychiatrica Scandinavica, 39(S180), 397–409.
   PubMedGoogle Scholar
• Ardito, R. B., & Rabellino, D. (2011). Therapeutic alliance and outcome of psychotherapy: Historical excursus, measurements, and prospects for research. Frontiers in Psychology, 2, 270.
   PubMed Web of Science ®Google Scholar
• Baggott, M. J., Coyle, J. R., Erowid, E., Erowid, F., & Robertson, L. C. (2011). Abnormal visual experiences in individuals with histories of hallucinogen use: A Web-based questionnaire. Drug and Alcohol Dependence, 114(1), 61–67.
   PubMed Web of Science ®Google Scholar
• Baggott, M. J. (2015). Psychedelics and creativity: A review of the quantitative literature (No. e1468). San Diego, CA: PeerJ PrePrints.
   Google Scholar
• Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. M. S., Johnson, M. W., & Griffiths, R. R. (2016). The challenging experience questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 30(12), 1279–1295.
   PubMed Web of Science ®Google Scholar
• Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015). Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. Journal of Psychopharmacology, 29(11), 1182–1190.
   PubMed Web of Science ®Google Scholar
• Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2017a). Neuroticism is associated with challenging experiences with psilocybin mushrooms. Personality and Individual Differences, 117, 155–160.
   PubMed Web of Science ®Google Scholar
• Barrett, F. S., Robbins, H., Smooke, D., Brown, J. L., & Griffiths, R. R. (2017b). Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions. Frontiers in Psychology, 8, 1238.
   PubMed Web of Science ®Google Scholar
• Bedi, G. (2018). 3,4-Methylenedioxymethamphetamine as a psychiatric treatment. JAMA Psychiatry. 21, 2018. doi:10.1001/jamapsychiatry.2018.0063
   Google Scholar
• Bhati, K. S. (2014). Effect of client-therapist gender match on the therapeutic relationship: An exploratory analysis. Psychological Reports, 115(2), 565–583.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, J. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., Johnson, M. W. (2016). Classic hallucinogens in the treatment of addictions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 250–258.
   PubMed Web of Science ®Google Scholar
• Bogenschutz, M. P., & Pommy, J. M. (2012). Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Testing and Analysis, 4(7-8), 543–555.
   PubMed Web of Science ®Google Scholar
• Bonny, H. L., & Pahnke, W. N. (1972). The use of music in psychedelic (LSD) psychotherapy. Journal of Music Therapy, 9(2), 64–87.
   Google Scholar
• Bonson, K. R. (2018). Regulation of human research with LSD in the United States (1949–1987). Psychopharmacology, 232(2), 591–604.
   Google Scholar
• Bonson, K. R., Buckholtz, J. W., & Murphy, D. L. (1996). Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology, 14(6), 425–436.
   PubMed Web of Science ®Google Scholar
• Bonson, K. R., & Murphy, D. L. (1995). Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behavioural Brain Research, 73(1-2), 229–233.
   Web of Science ®Google Scholar
• Bouso, J. C., Doblin, R., Farré, M., Alcázar, M. Á., & Gómez-Jarabo, G. (2008). MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Journal of Psychoactive Drugs, 40(3), 225–236.
   PubMed Web of Science ®Google Scholar
• Bouso, J. C., Dos Santos, R. G. Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018). Serotonergic psychedelics and personality: A systematic review of contemporary research. Neuroscience and Biobehavioral Reviews, 87, 118–132.
   Google Scholar
• Bravo, G., & Grob, C. (1996). Psychedelic psychotherapy. In B. Scotton & A. Chinen (Eds.), Textbook of transpersonal psychiatry and psychology (pp. 335–343). New York: Basic Books.
   Google Scholar
• Brodie, B. B., & Shore, P. A. (1957). A concept for a role of serotonin and norepinephrine as chemical mediators in the brain. Annals of the New York Academy of Sciences, 66(1), 631–642.
   PubMedGoogle Scholar
• Brown, R. T., Nicholas, C. R., Cozzi, N. V., Gassman, M. C., Cooper, K. M., Muller, D., … Hutson, P. R. (2017). Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clinical Pharmacokinetics, 56(12), 1543–1554.
   PubMed Web of Science ®Google Scholar
• Bugental, J. F. (1981). The search for authenticity: An existential-analytic approach to psychotherapy. New York, NY: Irvington Pub.
   Google Scholar
• Bullis, R. K. (1990). Swallowing the scroll: Legal implications of the recent Supreme Court peyote cases. Journal of Psychoactive Drugs, 22(3), 325–332.
   PubMed Web of Science ®Google Scholar
• Burks, D. J., & Robbins, R. (2012). Psychologists’ authenticity: Implications for work in professional and therapeutic settings. Journal of Humanistic Psychology, 52(1), 75–104.
   Web of Science ®Google Scholar
• Callaway, J. C., & Grob, C. S. (1998). Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination for severe adverse interactions. Journal of Psychoactive Drugs, 30(4), 367–369.
   PubMed Web of Science ®Google Scholar
• Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268–1278.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., … Taylor, D. (2016b). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., … Hobden, P. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138–2143.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology, 42(11), 2105.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015). LSD enhances suggestibility in healthy volunteers. Psychopharmacology, 232(4), 785–794.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., … Nutt, D. (2014). The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 8, 20.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., … Leech, R. (2016b). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences, 113(17), 4853–4858.
   PubMed Web of Science ®Google Scholar
• Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., … Leech, R. (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Scientific Reports, 7(1), 13187.
   PubMedGoogle Scholar
• Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology. 32(7), 725–731.
   PubMed Web of Science ®Google Scholar
• Carvalho, C., Caetano, J. M., Cunha, L., Rebouta, P., Kaptchuk, T. J., & Kirsch, I. (2016). Open-label placebo treatment in chronic low back pain: A randomized controlled trial. Pain, 157(12), 2766.
   PubMed Web of Science ®Google Scholar
• Chirico, A., Yaden, D. B., Riva, G., & Gaggioli, A. (2016). The potential of virtual reality for the investigation of awe. Frontiers in Psychology, 7, 1766.
   PubMed Web of Science ®Google Scholar
• Chwelos N., Blewett D. C., Smith C. & Hoffer A. (1959). Use of d-lysergic diethylamide in the treat-ment of alcoholism. Quarterly Journal of Studies of Alcohol, 20, 577–590.
   PubMedGoogle Scholar
• Clark, D. A., & Beck, A. T. (2010). Cognitive theory and therapy of anxiety and depression: Convergence with neurobiological findings. Trends in Cognitive Sciences, 14(9), 418–424.
   PubMed Web of Science ®Google Scholar
• Cohen, S. (1967). Psychotomimetic agents. Annual Review of Pharmacology, 7(1), 301–318.
   PubMedGoogle Scholar
• Danforth, A. L., Struble, C. M., Yazar-Klosinski, B., & Grob, C. S. (2016). MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 64, 237–249.
   PubMed Web of Science ®Google Scholar
• De Boer, D., Gijzels, M. J., Bosman, I. J., & Maes, R. A. A. (1999). More data about the new psychoactive drug 2C-B. Journal of Analytical Toxicology, 23(3), 227–228.
   PubMed Web of Science ®Google Scholar
• Denber, H. C., & Merlis, S. (1955). Studies on mescaline I. Action in schizophrenic patients. Psychiatric Quarterly, 29(1), 421–429.
   PubMedGoogle Scholar
• De Rios, M. D. (2003). The role of music in healing with hallucinogens: Tribal and western studies. Music Therapy Today, 4(3), 1–6.
   Google Scholar
• De Verges, G. (1974). Constitutional Law: Freedom of Religion: Peyote and the Native American Church. American Indian Law Review, 2(2), 71–79.
   Google Scholar
• Doblin, R. (1991). Pahnke’s “Good Friday Experiment:” A long-term follow-up and methodological critique. The Journal of Transpersonal Psychology, 23(1), 1–28.
   Google Scholar
• Dolder, P. C., Schmid, Y., Haschke, M., Rentsch, K. M., & Liechti, M. E. (2016). Pharmacokinetics and concentration-effect relationship of oral LSD in humans. International Journal of Neuropsychopharmacology, 19(1), 1–7.
   Web of Science ®Google Scholar
• Dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. (2016). Classical hallucinogens and neuroimaging: A systematic review of human studies: Hallucinogens and neuroimaging. Neuroscience & Biobehavioral Reviews, 71, 715–728.
   PubMed Web of Science ®Google Scholar
• Dyck, E. (2005). Flashback: Psychiatric experimentation with LSD in historical perspective. The Canadian Journal of Psychiatry, 50(7), 381–388.
   PubMed Web of Science ®Google Scholar
• Elvins, R., & Green, J. (2008). The conceptualization and measurement of therapeutic alliance: An empirical review. Clinical Psychology Review, 28(7), 1167–1187.
   PubMed Web of Science ®Google Scholar
• Erritzoe, D., & Richards, W. A. (2017). Lessons to be learned from early psychedelic therapy in Denmark. Nordic Journal of Psychiatry, 71(7), 487–488.
   PubMed Web of Science ®Google Scholar
• Fadiman, J. (2011). The psychedelic explorer's guide: Safe, therapeutic, and sacred journeys. Rochester, VT: Park Street Press.
   Google Scholar
• Ferrer, J. N. (2002). Revisioning transpersonal theory: A participatory vision of human spirituality. Albany, NY: SUNY Press.
   Google Scholar
• Forrester, M. B. (2006). Jimsonweed (Datura stramonium) exposures in Texas, 1998–2004. Journal of Toxicology and Environmental Health, Part A, 69(19), 1757–1762.
   PubMed Web of Science ®Google Scholar
• Frankl, V. E. (1954/1992). Man's search for meaning: An introduction to logotherapy. Boston, MA: Beacon Press.
   Google Scholar
• Frecska, E., Bokor, P., & Winkelman, M. (2016). The therapeutic potentials of ayahuasca: Possible effects against various diseases of civilization. Frontiers in Pharmacology, 7, 35.
   PubMed Web of Science ®Google Scholar
• Frecska, E., Móré, C. E., Vargha, A., & Luna, L. E. (2012). Enhancement of creative expression and entoptic phenomena as after-effects of repeated ayahuasca ceremonies. Journal of Psychoactive Drugs, 44(3), 191–199.
   PubMed Web of Science ®Google Scholar
• Friedman, M. (1976). Aiming at the self: The paradox of encounter and the human potential movement. Journal of Humanistic Psychology, 16(2), 5–34.
   Web of Science ®Google Scholar
• Gaddum, J. H. (1953). Antagonism between lysergic acid diethylamide and 5-hydroxytryptamine. The Journal of Physiology, 121(1), 15P–15P.
   Web of Science ®Google Scholar
• Garcia-Romeu, A., Barrett, F. S., Johnson. M. W., & Griffiths, R. R. (2017, June). Developing psilocybin as a potential pharmacotherapy: Identifying optimal dosing parameters. Poster presented at the College on Problems of Drug Dependence Annual Meeting in Montreal, Canada.
   Google Scholar
• Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews, 7(3), 157–164.
   PubMedGoogle Scholar
• Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016). Clinical applications of hallucinogens: A review. Experimental and Clinical Psychopharmacology, 24(4), 229.
   PubMed Web of Science ®Google Scholar
• Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease, 202(7), 513–520.
   PubMed Web of Science ®Google Scholar
• Gaston, E. T., & Eagle Jr, C. T. (1970). The function of music in LSD therapy for alcoholic patients. Journal of Music Therapy, 7(1), 3–19.
   Google Scholar
• Glennon, R. A., Titeler, M., & McKenney, J. D. (1984). Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences, 35(25), 2505–2511.
   PubMed Web of Science ®Google Scholar
• Gouzoulis-Mayfrank, E., Heekeren, K., Thelen, B., Lindenblatt, H., Kovar, K. A., Sass, H., & Geyer, M. A. (1998a). Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behavioural Pharmacology, 9(7), 561–566.
   PubMed Web of Science ®Google Scholar
• Gouzoulis-Mayfrank, E., Hermle, L., Thelen, B., & Sass, H. (1998b). History, rationale and potential of human experimental hallucinogenic drug research in psychiatry. Pharmacopsychiatry, 31(S 2), 63–68.
   PubMedGoogle Scholar
• Gouzoulis-Mayfrank, E., Schreckenberger, M., Sabri, O., Arning, C., Thelen, B., Spitzer, M., … Sass, H. (1999a). Neurometabolic effects of psilocybin, 3, 4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers: A double-blind, placebo-controlled PET study with [18F] FDG. Neuropsychopharmacology, 20(6), 565–581.
   PubMed Web of Science ®Google Scholar
• Gouzoulis-Mayfrank, E., Thelen, B., Habermeyer, E., Kunert, H. J., Kovar, K. A., Lindenblatt, H., … Sass, H. (1999b). Psychopathological, neuroendocrine and autonomic effects of 3, 4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers Results of an experimental double-blind placebo-controlled study. Psychopharmacology, 142(1), 41–50.
   PubMed Web of Science ®Google Scholar
• Greer, G. R., & Tolbert, R. (1998). A method of conducting therapeutic sessions with MDMA. Journal of Psychoactive Drugs, 30(4), 371–379.
   PubMed Web of Science ®Google Scholar
• Greiner, T., Burch, N. R., & Edelberg, R. (1958). Psychopathology and psychophysiology of minimal LSD-25 dosage: A preliminary dosage-response spectrum. AMA Archives of Neurology and Psychiatry, 79(2), 208–210.
   PubMedGoogle Scholar
• Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., … Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., … Klinedinst, M. A. (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology (Oxford, England), 32(1), 49–69.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology, 218(4), 649–665.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U. D., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621–632.
   PubMed Web of Science ®Google Scholar
• Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–283.
   PubMed Web of Science ®Google Scholar
• Grinspoon, L., & Bakalar, J. B. (1979). Psychedelic drugs reconsidered (pp. 221–223). New York: Basic Books.
   Google Scholar
• Grinspoon, L., & Bakalar, J. B. (1986). Can drugs be used to enhance the psychotherapeutic process?. American Journal of Psychotherapy, 40(3), 393.
   PubMed Web of Science ®Google Scholar
• Grinspoon, L., & Doblin, R. (2001). Psychedelics as catalysts of insight-oriented psychotherapy. Social Research, 68(3), 677–695.
   Web of Science ®Google Scholar
• Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68(1), 71–78.
   PubMed Web of Science ®Google Scholar
• Grof, S. (1994). LSD psychotherapy: Exploring the frontiers of the hidden mind. Alameda, CA: Hunter House, 1994, c1980.
   Google Scholar
• Grof, S. (1967). Psycholytic and Psychedelic Therapy with LSD: Toward an Integration of Ap proaches. Unpubl. paper presented at the 5th congress of the European Medical Society of Psycholylic Therapy (EPT) in Frankfurt (Germany) 1967.
   Google Scholar
• Grof, S., Soskin, R. A., Richards, W. A., & Kurland, A. A. (1973). DPT as an adjunct in psychotherapy of alcoholics. International pharmacopsychiatry, 8, 104–115.
   PubMedGoogle Scholar
• Guerra-Doce, E. (2015). Psychoactive substances in prehistoric times: Examining the archaeological evidence. Time and Mind, 8(1), 91–112.
   Web of Science ®Google Scholar
• Harman, W. W., McKim, R. H., Mogar, R. E., Fadiman, J., & Stolaroff, M. J. (1966). Psychedelic agents in creative problem-solving: A pilot study. Psychological Reports, 19(1), 211–227.
   PubMed Web of Science ®Google Scholar
• Harner, M. J., ed. (1973). Hallucinogens and Shamanism. Oxford: Oxford University Press.
   Google Scholar
• Hartogsohn, I. (2016). Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. Journal of Psychopharmacology, 30(12), 1259–1267.
   PubMed Web of Science ®Google Scholar
• Hartogsohn, I. (2017). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law, 3, 1–17.
   Google Scholar
• Hartogsohn, I. (2018). The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality and creativity. Frontiers in Neuroscience, 12, 129.
   PubMed Web of Science ®Google Scholar
• Havelock Ellis, H. (1897). A note on the phenomena of mescal intoxication. The Lancet, 149(3849), 1540–1542.
   Google Scholar
• Hayes, S. C., & Wilson, K. G. (1994). Acceptance and commitment therapy: Altering the verbal support for experiential avoidance. The Behavior Analyst, 17(2), 289–303.
   PubMed Web of Science ®Google Scholar
• Heffter, A. (1896). Ueber cacteenalkaloïde [On Cactus Alkaloids]. Berichte der deutschen chemischen Gesellschaft, 29, 216–227. http://dx.doi.org/10.1002/cber.18960290145
   Google Scholar
• Heffter, A. (1898). Ueber Pellote. Naunyn-Schmiedebergs. Archiv für Experimentalle Pathologie und Pharmakologie, 40, 385–429.
   Google Scholar
• Hendricks, P. S., Clark, C. B., Johnson, M. W., Fontaine, K. R., & Cropsey, K. L. (2014). Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Journal of Psychopharmacology, 28(1), 62–66.
   PubMed Web of Science ®Google Scholar
• Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D. W., & Johnson, M. W. (2015). Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 29(3), 280–288.
   PubMed Web of Science ®Google Scholar
• Hendricks, P. S., Crawford, M. S., Cropsey, K. L., Copes, H., Sweat, N. W., Walsh, Z., & Pavela, G. (2018). The relationships of classic psychedelic use with criminal behavior in the United States adult population. Journal of Psychopharmacology, 32(1), 37–48.
   PubMed Web of Science ®Google Scholar
• Hermle, L., Fünfgeld, M., Oepen, G., Botsch, H., Borchardt, D., Gouzoulis, E., … Spitzer, M. (1992). Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research. Biological Psychiatry, 32(11), 976–991.
   PubMed Web of Science ®Google Scholar
• Hermle, L., Gouzoulis-Mayfrank, E., & Spitzer, M. (1998). Blood flow and cerebral laterality in the mescaline model of psychosis. Pharmacopsychiatry, 31(S 2), 85–91.
   PubMedGoogle Scholar
• Hofmann, A. (1979). How LSD originated. Journal of Psychedelic Drugs, 11, 53–60.
   PubMed Web of Science ®Google Scholar
• Hofmann, A. (2013). LSD: My problem child. Oxford, UK: Oxford University Press.
   Google Scholar
• Horvath, A. O., & Luborsky, L. (1993). The role of the therapeutic alliance in psychotherapy. Journal of Consulting and Clinical Psychology, 61(4), 561–573.
   PubMed Web of Science ®Google Scholar
• Hunt, H. T. (1984). A cognitive psychology of mystical and altered-state experience. Perceptual and Motor Skills, 58(2), 467–513.
   Web of Science ®Google Scholar
• Huxley, A. (2009). The doors of perception & heaven and hell. New York, NY: HarperPerennial.
   Google Scholar
• James, W. (1902). The varieties of religious experience. New York, NY: Modern Library.
   Google Scholar
• Jehu, D. (1994). Patients as victims: Sexual abuse in psychotherapy and counselling. Chichester, UK: John Wiley & Sons.
   Google Scholar
• Johansen, P. Ø., & Krebs, T. S. (2009). How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. Journal of Psychopharmacology, 23(4), 389–391.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983–992.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017a). Long-term follow-up of psilocybin-facilitated smoking cessation. American Journal of Drug and Alcohol Abuse, 43(1), 55–60.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., Garcia-Romeu, A., Johnson, P. S., & Griffiths, R. R. (2017b). An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. Journal of Psychopharmacology, 31(7), 841–850.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., MacLean, K. A., Reissig, C. J., Prisinzano, T. E., & Griffiths, R. R. (2011). Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug & Alcohol Dependence, 115(1), 150–155.
   PubMed Web of Science ®Google Scholar
• Johnson, M. W., Richards, W. A., & Griffiths, R. R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620.
   PubMed Web of Science ®Google Scholar
• Johnstad, P. G. (2018). Powerful substances in tiny amounts: An interview study of psychedelic microdosing. Nordic Studies on Alcohol and Drugs, 35(1), 39–51.
   Web of Science ®Google Scholar
• Jones, P. N. (2005). The American Indian Church and its sacramental use of peyote: A review for professionals in the mental-health arena. Mental Health, Religion & Culture, 8(4), 277–290.
   Google Scholar
• Joyce, I. (2017). A comparative literature survey of psilocybin and LSD-25 metabolism. Retrieved from http://broncoscholar.library.cpp.edu/bitstream/handle/10211.3/193166/JoyceIan_LibrarResearchPaper2017.pdf
   Google Scholar
• Jung, C. G. (1936). The concept of the collective unconscious. Collected Works, 9(1), 42.
   Google Scholar
• Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., … Carhart-Harris, R. L. (2015). LSD enhances the emotional response to music. Psychopharmacology, 232(19), 3607–3614.
   PubMed Web of Science ®Google Scholar
• Kaelen, M., Giribaldi, B., Raine, J., Evans, L., Timmerman, C., Rodriguez, N., … Carhart-Harris, R. (2018). The hidden therapist: Evidence for a central role of music in psychedelic therapy. Psychopharmacology, 235(2), 505–519.
   PubMed Web of Science ®Google Scholar
• Kast, E. (1967). Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide. Psychiatric Quarterly, 41(4), 646–657.
   PubMed Web of Science ®Google Scholar
• Kast, E. C., & Collins, V. J. (1964). Study of lysergic acid diethylamide as an analgesic agent. Anesthesia & Analgesia, 43(3), 285–291.
   Web of Science ®Google Scholar
• Kavenská, V., & Simonová, H. (2015). Ayahuasca tourism: Participants in shamanic rituals and their personality styles, motivation, benefits and risks. Journal of Psychoactive Drugs, 47(5), 351–359.
   PubMed Web of Science ®Google Scholar
• Keeler, M. H., Ewing, J. A., & Rouse, B. A. (1971). Hallucinogenic effects of marijuana as currently used. American Journal of Psychiatry, 128(2), 213–216.
   PubMed Web of Science ®Google Scholar
• Khan, A., Bhat, A., Kolts, R., Thase, M. E., & Brown, W. (2010). Why has the antidepressant–placebo difference in antidepressant clinical trials diminished over the past three decades?. CNS Neuroscience & Therapeutics, 16(4), 217–226.
   PubMed Web of Science ®Google Scholar
• Kirschenbaum, H. (2004). Carl Rogers's life and work: An assessment on the 100th anniversary of his birth. Journal of Counseling & Development, 82(1), 116–124.
   Web of Science ®Google Scholar
• Klu¨ver, H. (1928). Studies on the eidetic type and on eidetic imagery. Psychology Bulletin, 25, 69–104.
   Google Scholar
• Korzybski, A. (1958). Science and sanity: An introduction to non-Aristotelian systems and general semantics (4th ed.). Brooklyn, NY: Institute of General Semantics.
   Google Scholar
• Kraehenmann, R., Pokorny, D., Vollenweider, L., Preller, K. H., Pokorny, T., Seifritz, E., & Vollenweider, F. X. (2017). Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology, 234(13), 2031–2046.
   PubMed Web of Science ®Google Scholar
• Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015). Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biological Psychiatry, 78(8), 572–581.
   PubMed Web of Science ®Google Scholar
• Kraehenmann, R., Schmidt, A., Friston, K., Preller, K. H., Seifritz, E., & Vollenweider, F. X. (2016). The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage: Clinical, 11, 53–60.
   PubMed Web of Science ®Google Scholar
• Krebs, T. S., & Johansen, P. Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26(7), 994–1002.
   PubMed Web of Science ®Google Scholar
• Krippner, S. (2000). The epistemology and technologies of shamanic states of consciousness. Journal of Consciousness Studies, 7(11-12), 93–118.
   Web of Science ®Google Scholar
• Krupitsky, E. M., Burakov, A. M., Dunaevsky, I. V., Romanova, T. N., Slavina, T. Y., & Grinenko, A. Y. (2007). Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. Journal of Psychoactive Drugs, 39(1), 13–19.
   PubMed Web of Science ®Google Scholar
• Krupitsky, E. M., & Grinenko, A. Y. (1997). Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. Journal of Psychoactive Drugs, 29(2), 165–183.
   PubMed Web of Science ®Google Scholar
• Krupitsky, E. M., Grinenko, A. Y., Berkaliev, T. N., Paley, A. I., Tetrov, U. N., Mushkov, K. A., & Borodikin, Y. S. (1992). The combination of psychedelic and aversive approaches in alcoholism treatment: the affective contra-attribution method. Alcoholism Treatment Quarterly, 9(1), 99–105.
   Google Scholar
• Krupnick, J. L., Sotsky, S. M., Simmens, S., Moyer, J., Elkin, I., & Pilkonis, P. A. (1996). The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: Findings in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. Journal of Consulting and Clinical Psychology, 64(3), 532–539.
   PubMed Web of Science ®Google Scholar
• Krystal, J. H., D'Souza, D. C., Petrakis, I. L., Belger, A., Berman, R. M., Charney, D. S., … Madonick, S. (1999). NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harvard Review of Psychiatry, 7(3), 125–143.
   PubMed Web of Science ®Google Scholar
• Kuo, H. I., Paulus, W., Batsikadze, G., Jamil, A., Kuo, M. F., & Nitsche, M. A. (2017). Acute and chronic effects of noradrenergic enhancement on transcranial direct current stimulation‐induced neuroplasticity in humans. The Journal of Physiology, 595(4), 1305–1314.
   PubMed Web of Science ®Google Scholar
• Kurland, A., Savage, C., Pahnke, W. N., Grof, S., & Olsson, J. E. (1971). LSD in the treatment of alcoholics. Pharmacopsychiatry, 4(02), 83–94.
   Google Scholar
• Labate, B. C. (2012). Paradoxes of ayahuasca expansion: The UDV–DEA agreement and the limits of freedom of religion. Drugs: Education, Prevention and Policy, 19(1), 19–26.
   Web of Science ®Google Scholar
• Labate, B. C., & Pacheco, G. (2010). Opening the portals of heaven: Brazilian ayahuasca music (Vol.4). Münster, Germany: LIT Verlag.
   Google Scholar
• Leary, T., Litwin, G. H., & Metzner, R. (1963). Reactions to psilocybjn administered in a supportive environment. The Journal of Nervous and Mental Disease, 137(6), 561–573.
   PubMed Web of Science ®Google Scholar
• Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016). LSD‐induced entropic brain activity predicts subsequent personality change. Human Brain Mapping, 37(9), 3203–3213.
   PubMed Web of Science ®Google Scholar
• Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017). Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology, 234(9-10), 1499–1510.
   PubMed Web of Science ®Google Scholar
• Leuner, H. (1962). Die experimentelle Psychose [The experimental psychosis]. Berlin: Springer-Verlag.
   Google Scholar
• Leuner, H. (1963). Psychotherapy with hallucinogens: A clinical report with special reference to the revival of emotional phases of childhood. In: R. Crocket, R. A. Sandison, & A. Walk (Eds.), Hallucinogenic drugs and their psychotherapeutic use (pp. 67–73). London: H.K. Lewis.
   Google Scholar
• Leuner, H. (1969). Guided affective imagery (GAI). American Journal of Psychotherapy, 23(1), 4–22.
   PubMed Web of Science ®Google Scholar
• Levine, J., & Ludwig, A. M. (1966). The hypnodelic treatment technique. International Journal of Clinical and Experimental Hypnosis, 14(3), 207–215.
   PubMed Web of Science ®Google Scholar
• Lewin, L. (1931/1998). Phantastica: A classic survey on the use and abuse of mind-altering plants. Rochester, VT: Park Street Press.
   Google Scholar
• Ludwig, A., Levine, J., Stark, L., & Lazar, R. (1969). A clinical study of LSD treatment in alcoholism. American Journal of Psychiatry, 126(1), 59–69.
   PubMed Web of Science ®Google Scholar
• Luna, L. E. (2011). Indigenous and mestizo use of ayahuasca: An overview. In R. G. Dos Santos (Ed.), The Ethnopharmacology of Ayahuasca (pp. 1–21). Trivandrum: Transworld Research Network.
   Google Scholar
• Lyttle, T. (1988). Drug based religions and contemporary drug taking. Journal of Drug Issues, 18(2), 271–284.
   Web of Science ®Google Scholar
• Lyvers, M., & Meester, M. (2012). Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner. Journal of Psychoactive Drugs, 44(5), 410–417.
   PubMed Web of Science ®Google Scholar
• MacLean, J. R., MacDonald, D. C., Byrne, U. P., & Hubbard, A. M. (1961). The use of LSD-25 in the treatment of alcoholism and other psychiatric problems. Quarterly Journal of Studies on Alcohol, 22, 34–45.
   PubMedGoogle Scholar
• MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 25(11), 1453–1461.
   PubMed Web of Science ®Google Scholar
• Majić, T., Schmidt, T. T., & Gallinat, J. (2015). Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Journal of Psychopharmacology, 29(3), 241–253.
   PubMed Web of Science ®Google Scholar
• Mangini, M. (1998). Treatment of alcoholism using psychedelic drugs: A review of the program of research. Journal of Psychoactive Drugs, 30(4), 381–418.
   PubMed Web of Science ®Google Scholar
• Martin, D. J., Garske, J. P., & Davis, M. K. (2000). Relation of the therapeutic alliance with outcome and other variables: A meta-analytic review. Journal of Consulting and Clinical Psychology, 68(3), 438–450.
   PubMed Web of Science ®Google Scholar
• Maslow, A. H. (1964). Religions, values, and peak-experiences. Columbus: Ohio State University Press.
   Google Scholar
• Maslow, A. H. (1968). Toward a psychology of being (2nd ed.). Oxford, England: D. Van Nostrand.
   Google Scholar
• Masters, R., & Houston, J. (2000). The varieties of psychedelic experience: The classic guide to the effects of LSD on the human psyche. Rochester, VT: Park Street Press..
   Google Scholar
• May, R. (Ed.). (1961). Existential psychology. New York, NY, US: Crown Publishing Group/Random House.
   Google Scholar
• McCusker, C. G. (2001). Cognitive biases and addiction: An evolution in theory and method. Addiction, 96(1), 47–56.
   PubMed Web of Science ®Google Scholar
• McKenna, D. J. (2004). Clinical investigations of the therapeutic potential of ayahuasca: Rationale and regulatory challenges. Pharmacology and therapeutics, 102(2), 111–129.
   PubMed Web of Science ®Google Scholar
• McKenna, D. J., Towers, G. N., & Abbott, F. (1984). Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β-carboline constituents of ayahuasca. Journal of Ethnopharmacology, 10(2), 195–223.
   PubMed Web of Science ®Google Scholar
• Merlis, S. (1957). The effects of mescaline sulfate in chronic schizophrenia. The Journal of Nervous and Mental Disease, 125(3), 432–433.
   PubMed Web of Science ®Google Scholar
• Metzner, R., Litwin, G., & Weil, G. (1965). The relation of expectation and mood to psilocybin reactions: A questionnaire study. Psychedelic Review 5, 3–39.
   Google Scholar
• Metzner, R. (1998). Hallucinogenic drugs and plants in psychotherapy and shamanism. Journal of Psychoactive Drugs, 30(4), 333–341.
   PubMed Web of Science ®Google Scholar
• Mitchell, S. W. (1896). Remarks on the effects of Anhelonium lewinii (the mescal button). British Medical Journal, 2(1875), 1625–1629.
   PubMedGoogle Scholar
• Mithoefer, M. C., Grob, C. S., & Brewerton, T. D. (2016). Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. The Lancet Psychiatry, 3(5), 481–488.
   PubMed Web of Science ®Google Scholar
• Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011). The safety and efficacy of ±3, 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology, 25(4), 439–452.
   PubMed Web of Science ®Google Scholar
• Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., … Doblin, R. (2013). Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3, 4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. Journal of Psychopharmacology, 27(1), 28–39.
   PubMed Web of Science ®Google Scholar
• Mogar, R. E. (1965). Current status and future trends in psychedelic (LSD) research. Journal of Humanistic Psychology, 5(2), 147–166.
   Google Scholar
• Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry, 67(11), 1735–1740.
   PubMed Web of Science ®Google Scholar
• Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non‐medical use of dissociative drugs. Drug Testing and Analysis, 6(7-8), 614–632.
   PubMed Web of Science ®Google Scholar
• Nau, F., Jr., Miller, J., Saravia, J., Ahlert, T., Yu, B., Happel, K. I., … Nichols, C. D. (2015). Serotonin 5-HT2 receptor activation prevents allergic asthma in a mouse model. American Journal of Physiology Lung Cellular and Molecular Physiology, 308, L191–L198.
   PubMed Web of Science ®Google Scholar
• Nau, F., Jr., Yu, B., Martin, D., & Nichols, C. D. (2013). Serotonin 5-HT2A receptor activation blocks TNF- mediated inflammation in vivo. PLoS One, 8, e75426.
   PubMed Web of Science ®Google Scholar
• Nichols, D. E. (1986). Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. Journal of Psychoactive Drugs, 18(4), 305–313.
   PubMed Web of Science ®Google Scholar
• Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131–181.
   PubMed Web of Science ®Google Scholar
• Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355.
   PubMed Web of Science ®Google Scholar
• Nichols, D. E., & Grob, C. S. (2018). Is LSD toxic? Forensic Science International, 284, 141–145.
   PubMed Web of Science ®Google Scholar
• Nichols, D. E., Johnson, M. W., & Nichols, C. D. (2017). Psychedelics as medicines: An emerging new paradigm. Clinical Pharmacology and Therapeutics, 101(2), 209–219.
   PubMed Web of Science ®Google Scholar
• Nichols, D. E., & Oberlender, R. (1990). Structure‐activity relationships of MDMA and related compounds: A new class of psychoactive drugs? Annals of the New York Academy of Sciences, 600(1), 613–623.
   PubMed Web of Science ®Google Scholar
• Nutt, D. J., King, L. A., & Nichols, D. E. (2013). Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nature Reviews Neuroscience, 14(8), 577.
   PubMed Web of Science ®Google Scholar
• Osmond, H. (1957). A review of the clinical effects of psychotomimetic agents. Annals of the New York Academy of Sciences, 66(1), 418–434.
   PubMedGoogle Scholar
• Ott, J. (2001). Pharmepena-psychonautics: human intranasal, sublingual and oral pharmacology of 5-methoxy-N, N-dimethyl-tryptamine. Journal of Psychoactive Drugs, 33(4), 403–407.
   PubMed Web of Science ®Google Scholar
• Pahnke, W. N. (1963). Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness: A thesis (Doctoral dissertation, Harvard University).
   Google Scholar
• Pahnke, W. N. (1969). The psychedelic mystical experience in the human encounter with death. Harvard Theological Review, 62(1), 1–21.
   Google Scholar
• Pahnke, W. N., Kurland, A. A., Unger, S., Savage, C., & Grof, S. (1970). The experimental use of psychedelic (LSD) psychotherapy. JAMA, 212(11), 1856–1863.
   PubMed Web of Science ®Google Scholar
• Pahnke, W. N., & Richards, W. A. (1966). Implications of LSD and experimental mysticism. Journal of Religion and Health, 5(3), 175–208.
   PubMedGoogle Scholar
• Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E., … de Araujo, D. B. (2015). The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PloS One, 10(2), e0118143.
   PubMed Web of Science ®Google Scholar
• Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C.,Novaes, M. M., Pessoa, J. A., & Tófoli,, L. F. (2018). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine. Advance online publication. doi:10.1017/S0033291718001356
   PubMedGoogle Scholar
• Passie, T. (1997). Psycholytic and psychedelic research 1931–1995: A complete international bibliography. Hannover, Germany: Laurentius.
   Google Scholar
• Passie, T. (2012). Healing with entactogens: Therapist and patient perspectives on MDMA-assisted group psychotherapy. Santa Cruz, CA: Multidisciplinary Association for Psychedelic Studies (MAPS).
   Google Scholar
• Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience & Therapeutics, 14, 295–314. http://dx.doi.org/10.1111/j .1755-5949.2008.00059.x
   PubMed Web of Science ®Google Scholar
• Phelps, J. (2017). Developing guidelines and competencies for the training of psychedelic therapists. Journal of Humanistic Psychology, 57(5), 450–487.
   Web of Science ®Google Scholar
• Popik, P., Layer, R. T., & Skolnick, P. (1995). 100 years of ibogaine: Neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacological Reviews, 47(2), 235–253.
   PubMed Web of Science ®Google Scholar
• Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., … Vollenweider, F. X. (2017). The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Current Biology, 27(3), 451–457.
   PubMed Web of Science ®Google Scholar
• Preller, K. H., Pokorny, T., Hock, A., Kraehenmann, R., Stämpfli, P., Seifritz, E., … Vollenweider, F. X. (2016). Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proceedings of the National Academy of Sciences, 113(18), 5119–5124.
   PubMed Web of Science ®Google Scholar
• Price, D. D., Finniss, D. G., & Benedetti, F. (2008). A comprehensive review of the placebo effect: Recent advances and current thought. Annual Reviews of Psychology, 59, 565–590.
   PubMed Web of Science ®Google Scholar
• Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003). Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 306(1), 73–83.
   PubMed Web of Science ®Google Scholar
• Rief, W., Nestoriuc, Y., Weiss, S., Welzel, E., Barsky, A. J., & Hofmann, S. G. (2009). Meta-analysis of the placebo response in antidepressant trials. Journal of Affective Disorders, 118(1), 1–8.
   PubMed Web of Science ®Google Scholar
• Richards, W. A. (1978). Mystical and archetypal experiences of terminal patients in DPT-assisted psychotherapy. Journal of Religion and Health, 17(2), 117–126.
   PubMedGoogle Scholar
• Richards, W. A. (2002). Entheogens in the study of mystical and archetypal experiences. Research in the Social Scientific Study of Religion, 13, 143–158.
   Google Scholar
• Richards, W. A. (2008). The phenomenology and potential religious import of states of consciousness facilitated by psilocybin. Archive for the Psychology of Religion, 30(1), 189–199.
   Google Scholar
• Richards W. A. (2015) Sacred knowledge: psychedelics and religious experiences. New York: Columbia University Press.
   Google Scholar
• Richards, W. A. (2017). Psychedelic psychotherapy: Insights from 25 years of research. Journal of Humanistic Psychology, 57(4), 323–337.
   Web of Science ®Google Scholar
• Richards, W. A., Grof, S., Goodman, L., & Kurland, A. (1972). LSD-assisted psychotherapy and the human encounter with death. Journal of Transpersonal Psychology, 4(2), 121–150.
   Google Scholar
• Richards, W. A., Rhead, J., DiLeo, F., Yensen, R., & Kurland, A. (1977). The peak experience variable in DPT-assisted psychotherapy with cancer patients. Journal of Psychedelic Drugs, 9, 1–10.
   Web of Science ®Google Scholar
• Richards, W. A., Rhead, J. C., Grof, S., Goodman, L. E., Di Leo, F., & Rush, L. (1980). DPT as an adjunct in brief psychotherapy with cancer patients. OMEGA-Journal of Death and Dying, 10(1), 9–26.
   Web of Science ®Google Scholar
• Riva, G. (2005). Virtual reality in psychotherapy. Cyberpsychology and Behavior, 8(3), 220–230.
   PubMedGoogle Scholar
• Riva, G., Baños, R. M., Botella, C., Mantovani, F., & Gaggioli, A. (2016). Transforming experience: the potential of augmented reality and virtual reality for enhancing personal and clinical change. Frontiers in Psychiatry, 7, 164.
   PubMed Web of Science ®Google Scholar
• Rizzo, A., & Koenig, S. T. (2017). Is clinical virtual reality ready for primetime? Neuropsychology, 31(8), 877.
   PubMed Web of Science ®Google Scholar
• Rogers, C. R. (1949). The attitude and orientation of the counselor in client-centered therapy. Journal of Consulting Psychology, 13(2), 82–94.
   PubMedGoogle Scholar
• Rogers, C. R. (1951). Client-centered therapy: Its current practice, implications, and theory, with chapters. Boston, MA: Houghton Mifflin.
   Google Scholar
• Rogers, C. R. (1957). The necessary and sufficient conditions of therapeutic personality change. Journal of Consulting Psychology, 21(2), 95–103.
   PubMedGoogle Scholar
• Roseman, L., Leech, R., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2014). The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers. Frontiers in Human Neuroscience, 8, 204.
   PubMed Web of Science ®Google Scholar
• Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2017). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Frontiers in Pharmacology, 8, 974.
   PubMed Web of Science ®Google Scholar
• Ross, L. K. (2017, January 18). I survived sexual abuse in the amazon — and victim blame at home. Retrieved from http://lilykayross.com/news/
   Google Scholar
• Ross, S. (2012). Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatric Clinics, 35(2), 357–374.
   Google Scholar
• Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., … Su, Z. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180.
   PubMed Web of Science ®Google Scholar
• Rothbaum, B. O., Price, M., Jovanovic, T., Norrholm, S. D., Gerardi, M., Dunlop, B., … Ressler, K. J. (2014). A randomized, double-blind evaluation of D-cycloserine or alprazolam combined with virtual reality exposure therapy for posttraumatic stress disorder in Iraq and Afghanistan War veterans. American Journal of Psychiatry, 171(6), 640–648.
   PubMed Web of Science ®Google Scholar
• Ruck, C. A., Bigwood, J., Staples, D., Ott, J., & Wasson, R. G. (1979). Entheogens. Journal of Psychedelic Drugs, 11(1-2), 145–146.
   PubMed Web of Science ®Google Scholar
• Rucker, J. J., Iliff, J., & Nutt, D. J. (2017). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology. Advance online publication. doi:10.1016/j.neuropharm.2017.12.040
   PubMed Web of Science ®Google Scholar
• Rucker, J. J., Jelen, L. A., Flynn, S., Frowde, K. D., & Young, A. H. (2016). Psychedelics in the treatment of unipolar mood disorders: A systematic review. Journal of Psychopharmacology, 30(12), 1220–1229.
   PubMed Web of Science ®Google Scholar
• Rudd, M., Vohs, K. D., & Aaker, J. (2012). Awe expands people’s perception of time, alters decision making, and enhances well-being. Psychological Science, 23(10), 1130–1136.
   PubMed Web of Science ®Google Scholar
• Rudgley, R. (1995). The archaic use of hallucinogens in Europe: An archaeology of altered states. Addiction, 90(2), 163–164.
   PubMed Web of Science ®Google Scholar
• Sampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., … Friedlander, P. (2017). Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. International Journal of Neuropsychopharmacology, 20(9), 698–711.
   PubMed Web of Science ®Google Scholar
• Sanches, R. F., de Lima Osório, F., Dos Santos, R. G., Macedo, L. R., Maia-de-Oliveira, J. P., Wichert-Ana, L., … Hallak, J. E. (2016). Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: A SPECT study. Journal of Clinical Psychopharmacology, 36(1), 77–81.
   PubMed Web of Science ®Google Scholar
• Sandison, R. A. (1954). Psychological aspects of the LSD treatment of the neuroses. Journal of Mental Science, 100(419), 508–515.
   PubMed Web of Science ®Google Scholar
• Sandison, R. A. (1963). Certainty and uncertainty in the LSD treatment of psychoneurosis. In R. Crocket, R. A. Sandison, & A. Walk (Eds.), Hallucinogenic drugs and their psychotherapeutic use (pp. 33–36). London: H.K. Lewis.
   Google Scholar
• Sanz, C., Zamberlan, F., Erowid, E., & Tagliazucchi, E. (2018). The experience elicited by hallucinogens presents the highest similarity to dreaming within a large database of psychoactive substance reports. Frontiers in Neuroscience, 12, 7.
   PubMed Web of Science ®Google Scholar
• Savage, C., Hughes, M. A., & Mogar, R. (1967). The effectiveness of psychedelic (LSD) therapy: A preliminary report. The British Journal of Social Psychiatry, 2(1), 59–66.
   Google Scholar
• Savage, C., & McCabe, O. L. (1973). Residential psychedelic (LSD) therapy for the narcotic addict: A controlled study. Archives of General Psychiatry, 28(6), 808–814.
   PubMed Web of Science ®Google Scholar
• Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., … Liechti, M. E. (2015). Acute effects of lysergic acid diethylamide in healthy subjects. Biological Psychiatry, 78(8), 544–553.
   PubMed Web of Science ®Google Scholar
• Schmid, Y., & Liechti, M. E. (2018). Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology, 235(2), 535–545.
   PubMed Web of Science ®Google Scholar
• Schultes, R. E. (1969). Hallucinogens of plant origin. Science, 163, 245–254.
   PubMed Web of Science ®Google Scholar
• Schultes, R. E. (1998). Antiquity of the use of new world hallucinogens. The Heffter Review of Psychedelic Research, 1, 1–7.
   Google Scholar
• Schultes, R. E., & Hofmann, A. (1992). Plants of the Gods: Their sacred. Healing and hallucinogenic powers. Rochester, NY: Healing Arts Press.
   Google Scholar
• Sellers, E. M., & Leiderman, D. B. (2018). Psychedelic drugs as therapeutics: No illusions about the challenges. Clinical Pharmacology and Therapeutics, 103(4), 561–564.
   PubMed Web of Science ®Google Scholar
• Sessa, B. (2008). Is it time to revisit the role of psychedelic drugs in enhancing human creativity? Journal of Psychopharmacology, 22(8), 821–827.
   PubMed Web of Science ®Google Scholar
• Sessa B. (2016) The history of psychedelics in medicine. In M. von Heyden, H. Jungaberle, & T. Majić (Eds.), Handbuch psychoaktive substanzen. Springer reference psychologie. Springer reference psychologie. Berlin, Heidelberg, Springer.
   Google Scholar
• Sessa, B. (2017). MDMA and PTSD treatment:“PTSD: From novel pathophysiology to innovative therapeutics. Neuroscience Letters, 649, 176–180.
   PubMed Web of Science ®Google Scholar
• Sewell, R. A., Halpern, J. H., & Pope, H. G. (2006). Response of cluster headache to psilocybin and LSD. Neurology, 66(12), 1920–1922.
   PubMed Web of Science ®Google Scholar
• Shulgin, A., & Shulgin, A. (1991). PiHKAL: A chemical love story. Berkeley: Transform Press.
   Google Scholar
• Shulgin, A., & Shulgin, A. (1997). TiHKAL: The continuation (Vol. 546). Berkeley: Transform Press.
   Google Scholar
• Sinke, C., Halpern, J. H., Zedler, M., Neufeld, J., Emrich, H. M., & Passie, T. (2012). Genuine and drug-induced synesthesia: A comparison. Consciousness and Cognition, 21(3), 1419–1434.
   PubMed Web of Science ®Google Scholar
• Smart, R. G., & Bateman, K. (1967). Unfavourable reactions to LSD: A review and analysis of the available case reports. Canadian Medical Association Journal, 97(20), 1214
   PubMed Web of Science ®Google Scholar
• Smart, R. G., Storm, T., Baker, E. F., & Solursh, L. (1966). A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. Quarterly Journal of Studies on Alcohol, 27(3), 469–482.
   PubMedGoogle Scholar
• Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., … Riba, J. (2016). Exploring the therapeutic potential of Ayahuasca: Acute intake increases mindfulness-related capacities. Psychopharmacology, 233(5), 823–829.
   PubMed Web of Science ®Google Scholar
• Spitzer, M., Thimm, M., Hermle, L., Holzmann, P., Kovar, K. A., Heimann, H., … Schneider, F. (1996). Increased activation of indirect semantic associations under psilocybin. Biological Psychiatry, 39(12), 1055–1057.
   PubMed Web of Science ®Google Scholar
• Stace, W. T. (1960). Mysticism and philosophy. New York: MacMillan Press.
   Google Scholar
• Strassman, R. J. (1984). Adverse reactions to psychedelic drugs. A review of the literature. Journal of Nervous and Mental Disease, 172(10), 577–595.
   PubMed Web of Science ®Google Scholar
• Strassman, R. J., & Qualls, C. R. (1994). Dose-response study of N, N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects. Archives of General Psychiatry, 51(2), 85–97.
   PubMed Web of Science ®Google Scholar
• Strassman, R. J., Qualls, C. R., & Berg, L. M. (1996). Differential tolerance to biological and subjective effects of four closely spaced doses of N, N-dimethyltryptamine in humans. Biological Psychiatry, 39(9), 784–795.
   PubMed Web of Science ®Google Scholar
• Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H., & Kellner, R. (1994). Dose-response study of N, N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale. Archives of General Psychiatry, 51(2), 98–108.
   PubMed Web of Science ®Google Scholar
• Swanson, L. R. (2018). Unifying theories of psychedelic drug effects. Frontiers in Pharmacology, 9, 172.
   PubMed Web of Science ®Google Scholar
• Swift, T. C., Belser, A. B., Agin-Liebes, G., Devenot, N., Terrana, S., Friedman, H. L., … Ross, S. (2017). Cancer at the dinner table: Experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. Journal of Humanistic Psychology, 57(5), 488–519.
   Web of Science ®Google Scholar
• Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012). Prediction of psilocybin response in healthy volunteers. PLoS One, 7(2), e30800.
   PubMed Web of Science ®Google Scholar
• Tagliazucchi, E., Carhart‐Harris, R., Leech, R., Nutt, D., & Chialvo, D. R. (2014). Enhanced repertoire of brain dynamical states during the psychedelic experience. Human Brain Mapping, 35(11), 5442–5456.
   PubMed Web of Science ®Google Scholar
• Tagliazucchi, E., Roseman, L., Kaelen, M., Orban, C., Muthukumaraswamy, S. D., Murphy, K., … Bullmore, E. (2016). Increased global functional connectivity correlates with LSD-induced ego dissolution. Current Biology, 26(8), 1043–1050.
   PubMed Web of Science ®Google Scholar
• Thomas, G., Lucas, P., Capler, N. R., Tupper, K. W., & Martin, G. (2013). Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Current Drug Abuse Reviews, 6(1), 30–42.
   PubMedGoogle Scholar
• Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Maguire, P., Stadelmann, O., & Angst, J. (1997). Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology, 16(5), 357–372.
   PubMed Web of Science ®Google Scholar
• Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F., Bäbler, A., Vogel, H., & Hell, D. (1998). Psilocybin induces schizophrenia‐like psychosis in humans via a serotonin‐2 agonist action. Neuroreport, 9(17), 3897–3902.
   PubMed Web of Science ®Google Scholar
• Walach, H., Sadaghiani, C., Dehm, C., & Bierman, D. (2005). The therapeutic effect of clinical trials: Understanding placebo response rates in clinical trials–a secondary analysis. BMC Medical Research Methodology, 5(1), 26.
   PubMedGoogle Scholar
• Waldman, A. (2018). A really good day: How microdosing made a mega difference in my mood, my marriage, and my life. New York, NY: Anchor Books.
   Google Scholar
• Walsh, Z., Hendricks, P. S., Smith, S., Kosson, D. S., Thiessen, M. S., Lucas, P., & Swogger, M. T. (2016). Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use. Journal of Psychopharmacology, 30(7), 601–607.
   PubMed Web of Science ®Google Scholar
• Wasson, R. G. (1961). The hallucinogenic fungi of Mexico: an inquiry into the origins of the religious idea among primitive peoples. Botanical Museum Leaflets, Harvard University, 19(7), 137–162.
   Google Scholar
• Wasson, R. G., Hofmann, A., & Ruck, C. A. (2008). The road to Eleusis: Unveiling the secret of the mysteries. Berkeley, CA: North Atlantic Books.
   Google Scholar
• Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. Journal of Humanistic Psychology, 57(5), 520–564.
   Web of Science ®Google Scholar
• Weise, D., Mann, J., Rumpf, J. J., Hallermann, S., & Classen, J. (2016). Differential regulation of human paired associative stimulation-induced and theta-burst stimulation-induced plasticity by L-type and T-type Ca2+ channels. Cerebral Cortex, 27(8), 4010–4021.
   Web of Science ®Google Scholar
• Weiss, M., Gaston, L., Propst, A., Wisebord, S., & Zicherman, V. (1997). The role of the alliance in the pharmacologic treatment of depression. The Journal of clinical psychiatry, 58(5), 196–204.
   PubMed Web of Science ®Google Scholar
• Winstock, A. R., Kaar, S., & Borschmann, R. (2014). Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample. Journal of Psychopharmacology, 28(1), 49–54.
   PubMed Web of Science ®Google Scholar
• Witkiewitz, K., Marlatt, G. A., & Walker, D. (2005). Mindfulness-based relapse prevention for alcohol and substance use disorders. Journal of Cognitive Psychotherapy, 19(3), 211–228.
   Google Scholar
• Woolley, D. W., & Shaw, E. (1954). Some neurophysiological aspects of serotonin. British Medical Journal, 2(4880), 122–126.
   PubMedGoogle Scholar
• Wright, J. H. (2006). Cognitive behavior therapy: Basic principles and recent advances. Focus, 4(2), 173–178.
   Google Scholar
• Yu, B., Becnel, J., Zerfaoui, M., Rohatgi, R., Boulares, A. H., & Nichols, C. D. (2008). Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-induced inflammation with extraor-dinary potency. The Journal of Pharmacology and Experimental Ther-apeutics, 327, 316–323.
   PubMed Web of Science ®Google Scholar